{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:40:34Z","timestamp":1773283234709,"version":"3.50.1"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            New therapeutic strategies are needed to combat the emergence of infections due to multidrug-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Neisseria gonorrhoeae<\/jats:named-content>\n            . In this study, fosfomycin (FOS) was tested against 89\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">N. gonorrhoeae<\/jats:named-content>\n            isolates using the Etest method, showing MIC\n            <jats:sub>50<\/jats:sub>\n            \/MIC\n            <jats:sub>90<\/jats:sub>\n            s of only 8\/16 \u03bcg\/ml (range, \u22641 to 32 \u03bcg\/ml). FOS in combination with ceftriaxone (CRO) or azithromycin (AZT) was then evaluated using the checkerboard method for eight strains, including\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">N. gonorrhoeae<\/jats:named-content>\n            F89 (CRO-resistant) and AZT-HLR (high-level AZT-resistant). All combinations that included FOS gave indifferent effects (fractional inhibitory concentration [FIC] index values, 1.2 to 2.3 for FOS plus CRO, 1.8 to 3.2 for FOS plus AZT). Time-kill experiments for FOS, CRO, AZT, and their combinations (at 0.5\u00d7, 1\u00d7, 2\u00d7, and 4\u00d7 the MIC) were performed against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">N. gonorrhoeae<\/jats:named-content>\n            strain ATCC 49226, one\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">N. gonorrhoeae<\/jats:named-content>\n            multiantigen sequence typing (NG-MAST) sequence type 1407 (ST1407) strain, F89, and AZT-HLR. For all strains, at 24 h, the results indicated that (i) FOS was bactericidal at 2\u00d7 the MIC, but after &gt;24 h, there was regrowth of bacteria; (ii) CRO was bactericidal at 0.5\u00d7 the MIC; (iii) AZT was bactericidal at 4\u00d7 the MIC; (iv) CRO plus AZT was less bactericidal than was CRO alone; (v) FOS plus AZT was bactericidal at 2\u00d7 the MIC; and (vi) CRO plus AZT and FOS plus CRO were both bactericidal at 0.5\u00d7 the MIC, but FOS plus CRO had more rapid effects. FOS is appealing for use in the management of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">N. gonorrhoeae<\/jats:named-content>\n            infections because of its single and oral formulation. However, our results suggest it be used in combination with CRO. After the appropriate clinical trials are conducted, this strategy could be implemented for the treatment of infections due to isolates possessing resistance to CRO and\/or AZT.\n          <\/jats:p>","DOI":"10.1128\/aac.04536-14","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T08:32:47Z","timestamp":1419928367000},"page":"1605-1611","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":46,"title":["<i>In Vitro<\/i>\n            Activity of Fosfomycin Alone and in Combination with Ceftriaxone or Azithromycin against Clinical Neisseria gonorrhoeae Isolates"],"prefix":"10.1128","volume":"59","author":[{"given":"Christoph","family":"Hauser","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland"},{"name":"Institute for Infectious Diseases, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Hirzberger","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[{"name":"\u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansjakob","family":"Furrer","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-5421","authenticated-orcid":false,"given":"Andrea","family":"Endimiani","sequence":"additional","affiliation":[{"name":"Institute for Infectious Diseases, University of Bern, Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"Global incidence and prevalence of selected curable sexually transmitted infections\u20132008","author":"World Health Organization (WHO)","year":"2012","unstructured":"World Health Organization (WHO). 2012. Global incidence and prevalence of selected curable sexually transmitted infections\u20132008. World Health Organization, Geneva, Switzerland. http:\/\/apps.who.int\/iris\/bitstream\/10665\/75181\/1\/9789241503839_eng.pdf?ua=1."},{"key":"e_1_3_2_3_2","volume-title":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae","author":"World Health Organization (WHO)","year":"2012","unstructured":"World Health Organization (WHO). 2012. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. World Health Organization, Geneva, Switzerland. http:\/\/whqlibdoc.who.int\/publications\/2012\/9789241503501_eng.pdf?ua=1."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks188"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-14"},{"key":"e_1_3_2_6_2","first-page":"590","article-title":"Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","author":"Centers for Diseases Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Diseases Control and Prevention (CDC). 2012. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 61:590\u2013594.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462412472837"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02093-13"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05760-11"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.63"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-11"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1112456"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku118"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"pii=19792","DOI":"10.2807\/ese.16.06.19792-en","article-title":"Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations","volume":"16","author":"Unemo M","year":"2011","unstructured":"Unemo M, Golparian D, Hestner A. 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 16:pii=19792. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=19792.","journal-title":"Euro Surveill"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1071\/SH13077"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt017"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"pii=20200","DOI":"10.2807\/ese.17.25.20200-en","article-title":"Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia","volume":"17","author":"Unemo M","year":"2012","unstructured":"Unemo M, Golparian D, Potocnik M, Jeverica S. 2012. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 17:pii=20200. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20200.","journal-title":"Euro Surveill"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"pii=20862","DOI":"10.2807\/1560-7917.ES2014.19.30.20862","article-title":"Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg)","volume":"19","author":"Golparian D","year":"2014","unstructured":"Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, Fredlund H, Unemo M. 2014. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill 19:pii=20862. http:\/\/www.eurosurveillance.org\/ViewArticle.aspx?ArticleId=20862.","journal-title":"Euro Surveill"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/527442"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0143-y"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.05.019"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit704"},{"key":"e_1_3_2_23_2","first-page":"107","article-title":"Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt","volume":"14","author":"Scaglione F","year":"1994","unstructured":"Scaglione F, Cicchetti F, Demartini G, Arcidiacono M. 1994. Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt. Int J Clin Pharmacol Res 14:107\u2013109.","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt540"},{"key":"e_1_3_2_25_2","first-page":"154","article-title":"The activity of rosoxacin, fosfomycin, cefotiam, and spectinomycin on \u03b2-lactamase producing Neisseria gonorrhoeae","volume":"60","author":"Dickgiesser N","year":"1984","unstructured":"Dickgiesser N, Kuntz P. 1984. The activity of rosoxacin, fosfomycin, cefotiam, and spectinomycin on \u03b2-lactamase producing Neisseria gonorrhoeae. Br J Vener Dis 60:154\u2013156.","journal-title":"Br J Vener Dis"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-106"},{"key":"e_1_3_2_27_2","volume-title":"Clinical breakpoints, version 4.0, 2014","author":"EUCAST","year":"2014","unstructured":"EUCAST. 2014. Clinical breakpoints, version 4.0, 2014. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden."},{"key":"e_1_3_2_28_2","volume-title":"CLSI document M100\u2013S24","author":"CLSI","year":"2014","unstructured":"CLSI. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100\u2013S24. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.9.4321-4327.2005"},{"key":"e_1_3_2_30_2","volume-title":"Textbook of diagnostic microbiology","author":"Mahon CR","year":"2000","unstructured":"Mahon CR, Manuselis G. 2000. Textbook of diagnostic microbiology, 2nd ed. W. B. Saunders Company, Philadelphia, PA.","edition":"2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks449"},{"key":"e_1_3_2_32_2","first-page":"42","article-title":"Accuracy of plate counts","volume":"17","author":"Scott S","year":"2011","unstructured":"Scott S. 2011. Accuracy of plate counts. J Validation Technol 17:42\u201346.","journal-title":"J Validation Technol"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.5.1073"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr466"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1360-5"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-013-0597-6"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2013.10.007"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02463-14"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.9.1375"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1159\/000222063","article-title":"Treatment of acute and subacute gonococcal urethritis with fosfomycin","volume":"23","author":"L\u00f3pez-Grac\u00eda J","year":"1977","unstructured":"L\u00f3pez-Grac\u00eda J. 1977. Treatment of acute and subacute gonococcal urethritis with fosfomycin. Chemotherapy 23(Suppl 1):S293\u2013S300.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.08.013"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70143-9"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1201\/b13787-32","volume-title":"Kucers' the use of antibiotics","author":"McDowell L","year":"2010","unstructured":"McDowell L, Kim BN, Paterson DL. 2010. Ceftriaxone, p 351\u2013389. In Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Patterson DL, Pfaller MA (ed), Kucers' the use of antibiotics, 6th ed. CRC Press, Boca Raton, FL.","edition":"6"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.117"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04536-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04536-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:50:48Z","timestamp":1645483848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04536-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/AAC.04536-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04536-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"2014-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}